Aurisco Pharmaceutical Co.,Ltd. (SHA:605116)

Market Cap	11.02B +32.0%
Revenue (ttm)	1.70B +15.0%
Net Income	449.21M +26.6%
EPS	1.10 +23.6%
Shares Out	406.18M
PE Ratio	24.65
Forward PE	19.94
Dividend	0.29 (1.05%)
Ex-Dividend Date	Jun 20, 2025

Volume	7,295,700
Average Volume	9,772,189
Open	27.12
Previous Close	27.12
Day's Range	26.20 - 27.60
52-Week Range	20.18 - 35.58
Beta	-0.08
RSI	44.73
Earnings Date	Apr 17, 2026

About Aurisco Pharmaceutical

Aurisco Pharmaceutical Co.,Ltd. engages in the research, development, production and sales of special complex APIs, pharmaceutical intermediates and preparations worldwide. The company offers APIs and intermediates of respiratory system, cardiovascular, anti-infection, nervous system, anti-tumor, and women's health drugs. It also provides dexamethasone is used to treat skin diseases; fluticasone propionate preparations are used to treat asthma and allergic rhinitis; fluticasone furoate preparations are used to treat asthma, allergic rhinitis, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 1,784
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 605116

Financial Performance

In 2025, Aurisco Pharmaceutical's revenue was 1.70 billion, an increase of 15.03% compared to the previous year's 1.48 billion. Earnings were 449.21 million, an increase of 26.61%.